相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selective tissue targeting of synthetic nucleic acid drugs
Punit P. Seth et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo
Annabelle Biscans et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
Maire F. Osborn et al.
NUCLEIC ACIDS RESEARCH (2019)
Structural Determinants for the Interactions of Chemically Modified Nucleic Acids with the Stabilin-2 Clearance Receptor
Hans Gaus et al.
BIOCHEMISTRY (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver
Colton M. Miller et al.
NUCLEIC ACID THERAPEUTICS (2018)
RNA-mediated therapies in myotonic dystrophy
Sarah J. Overby et al.
DRUG DISCOVERY TODAY (2018)
Evaluation of the effect of 2 '-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice
Thazha P. Prakash et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation
Michael Lykke Hvam et al.
MOLECULAR THERAPY (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
Karsten Schmidt et al.
NUCLEIC ACIDS RESEARCH (2017)
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
Dominic Jauvin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
The expression of the rare caveolin-3 variant T78M alters cardiac ion channels function and membrane excitability
Giulia Campostrini et al.
CARDIOVASCULAR RESEARCH (2017)
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth
Tayeba Khan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Carrier-free Gene Silencing by Amphiphilic Nucleic Acid Conjugates in Differentiated Intestinal Cells
Elena Moroz et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Fatty acid binding into the highest affinity site of human serum albumin observed in molecular dynamics simulation
Bruno Rizzuti et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2015)
Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1
Sanjay K. Pandey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis
Anne Plum et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals
Gene Hung et al.
NUCLEIC ACID THERAPEUTICS (2013)
Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group
Natalya S. Petrova et al.
NUCLEIC ACIDS RESEARCH (2012)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Christian Wolfrum et al.
NATURE BIOTECHNOLOGY (2007)
Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis
Ulrich Kragh-Hansen et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Insulin detemir: from concept to clinical experience
P Home et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
The extraordinary ligand binding properties of human serum albumin
M Fasano et al.
IUBMB LIFE (2005)
Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration
MJ Graham et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation
MK Bijsterbosch et al.
NUCLEIC ACIDS RESEARCH (2000)
Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion
M Ellmerer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2000)
分享论文
